WithdrawnPhase 2

Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)

Stopped: Study stopped following management decision

Spain0Started 2017-01

Plain-language summary

This clinical investigation aims at demonstrating that NCX-4240 is effective and safe in decreasing the number of days where adenoviral conjunctivis is detected in the eye and in reducing the duration and/or the severity of the signs and symptoms of adenoviral conjunctivis

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * With uni-or bilateral acute adenoviral conjunctivis as diagnostised with adenoplus test * Conjunctivis signs and symptoms in at least one eye AND positive adenoplus test in at least one eye whatever signs/symptoms and positive adenoplus test are from the same eye or not Exclusion Criteria: * Negative results with adenoplus test in both eyes * a suspected bacterial, fungal, herpes, chlamydia or acanthamoeba co-infection, based on clinical investigation

What they're measuring

Viral eradication time NCX 4240 versus Placebo

Timeframe: 21 days

Trial details

NCT IDNCT03009799

SponsorNicOx

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-08

View on ClinicalTrials.gov More Adenoviral Conjunctivitis trials